Trials / Completed
CompletedNCT02035137
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium · Academic / Other
- Sex
- All
- Age
- 2 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 131I-MIBG | |
| DRUG | Vincristine | |
| DRUG | Irinotecan | |
| DRUG | Vorinostat |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2021-02-26
- Completion
- 2021-02-26
- First posted
- 2014-01-14
- Last updated
- 2022-06-08
- Results posted
- 2022-06-08
Locations
14 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02035137. Inclusion in this directory is not an endorsement.